Anti-cd98 antibodies and antibody drug conjugates
US-2020121803-A1 · Apr 23, 2020 · US
Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
US11899019B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11899019-B2 |
| Application number | US-201816623573-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 7, 2018 |
| Priority date | Nov 7, 2017 |
| Publication date | Feb 13, 2024 |
| Grant date | Feb 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating cancer in a subject, comprising: administering an anti-PD-1 antibody or an anti-PD-L1 antibody in combination with a LAT1 inhibitor to the subject, wherein the LAT1 inhibitor is O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof.
Assignees
Inventors
Classifications
for cancer · CPC title
of the lungs · CPC title
- G01N33/5759Primary
involving compounds localised on the membrane of tumour or cancer cells · CPC title
of the liver or pancreas · CPC title
of the large intestine, e.g. colon, rectum or anus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11899019B2 cover?
- Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting…
- Who is the assignee on this patent?
- J Pharma Co Ltd, Univ Gunma Nat Univ Corp, Univ Osaka
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5759. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).